(Q37983922)

26 August 2017

Telaprevir for the treatment of hepatitis C. (English)

1 reference

26 August 2017

2

Stefan Zeuzem

1 reference

26 August 2017

Nicole Forestier

1

1 reference

PubMed ID

22332992

26 August 2017

language of work or name

English

0 references

publication date

15 February 2012

1 reference

Expert Opinion on Pharmacotherapy

26 August 2017

1 reference

26 August 2017

13

1 reference

26 August 2017

4

1 reference

26 August 2017

593-606

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

26 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Novel insights into hepatitis C virus replication and persistence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Replication of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.660524

10.1517/14656566.2012.660524

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22332992